The 2022 5th edition is not conceptually very different from the previous 2017 classification of odontogenic lesions. The odontogenic tumor classification, like earlier editions, is mainly divided into two categories, based on biologic behavior, as malignant and benign. Unlike past editions where malignant odontogenic tumors were discussed first, in the current edition, the odontogenic tumors are still organized by tumor behavior, but the malignant tumors are placed last. Benign tumors are classified into three major categories according to their histogenetic origin; epithelial, mesenchymal and mixed types. The only new entity added to benign epithelial tumors is adenoid ameloblastoma [2]. Additionally, subtypes of certain odontogenic tumors and odontogenic cysts are more clearly defined and explained. Some challenging aspects of the 2017 classification still remain uncertain, controversial and debatable, such as the classification of metastasizing ameloblastoma, ameloblastic fibroodontoma/dentinoma, and the mural type of unicystic ameloblastoma [3,4]. The odontogenic cyst classification, which was removed in the 2005 3rd edition and added in 2017 4th edition, continues in the new edition with the same entities. Surgical ciliated cyst, not a new entity but new to the classification, has been added to cysts of the jaws.
The aim of this review is to discuss updates in the new 2022 WHO odontogenic lesions classification, outlining changes from the 2017 WHO classification and summarizing the essential diagnostic criteria and current molecular advances. Although not an odontogenic cyst, we will also emphasize the new entry of surgical ciliated cysts to the cyst classification of the jaws and nasopalatine duct cyst. Table I summarizes the current classification of odontogenic tumors and cysts of the jaws [1].
Table I: 2022 WHO classification of odontogenic tumors and cysts of the jaws.
ODONTOGENIC TUMOURS
Table II highlights the essential diagnostic criteria along
with age, gender, localization preference of all odontogenic
tumors.
Table II: Age, gender, localization preferences, and essential diagnostic criteria of odontogenic tumors, modified from the 2022 WHO classification [1].
Benign Epithelial Odontogenic Tumors
Adenomatoid odontogenic tumor (AOT) has molecular
updates and a detailed differential diagnostic section.
It is emphasized that some odontogenic lesions, such
as odontomas, adenoid ameloblastoma (new entity),
adenomatoid odontogenic hamartoma, and adenomatoid
dentinoma (the last two not being included in the
2022 classification) may contain AOT-like areas [5,6],
and conversely AOT can include calcifying epithelial
odontogenic tumor-like areas [7]. To avoid misdiagnosis
due to the histopathologic overlapping, detailed clinicradiologic
evaluation is necessary as with all bone lesions.
Regarding the molecular profile, KRAS mutations and
MAPK pathway activation are the most common features
of AOT that shows KRAS p.G12V and p.G12R mutations
in about 70% of cases [8].
Squamous odontogenic tumor has no major changes from the previous edition.
Calcifying epithelial odontogenic tumor (CEOT) has relatively important changes in that three subtypes have been described as clear cell CEOT, cystic/microcystic CEOT, and non-calcifying/Langerhans cell-rich CEOT [1]. In the previous edition, these different variants were explained in the histopathological and macroscopic features sections, but they were not included as separate subtypes [4]. However, no clear differential diagnostic criteria are proposed to separate the non-calcifying/Langerhans cellrich CEOT from the amyloid-rich subtype of odontogenic fibroma. These are likely the same tumor but are classified as CEOT by some and as central odontogenic fibroma by others. However, most cases are more suitable for amyloidrich odontogenic fibroma in terms of morphological and molecular features [9]. Although different mutations (PTCH1, ABMN, PTEN, CDKN2A, JAK3, MET) have been reported in studies for CEOT, none of them currently affect treatment and diagnosis [1].
Ameloblastoma, Unicystic, still has three subtypes according to the distribution of the proliferation of the ameloblastomatous epithelium: luminal, intraluminal and mural. There is general agreement that the first two subtypes can be treated conservatively, but the last one might need to be treated as ameloblastoma [10]. The debate continues on whether the mural type is a type of conventional ameloblastoma or not. However, in the new and previous edition it was left under unicystic ameloblastoma.
BRAF p.V600E mutations have been found in all types [11]. The mural type seems to be somewhere in between conventional and unicystic ameloblastoma in terms of recurrence and might require consideration of more extensive surgery for aggressive and destructive lesions [12]. In addition, BRAF-targeted therapy can be a consideration for the treatment of mutation-positive cases [13].
Ameloblastoma, Extraosseous/peripheral still has a separate entity status while other peripheral odontogenic lesions do not have such distinction, but this has not changed from previous editions. Peripheral ameloblastoma is explained in detail without any major changes from the previous edition.
Ameloblastoma, Conventional, the most common odontogenic neoplasm, excluding odontoma that is considered a hamartoma, is a benign but locally infiltrative neoplasm composed of ameloblast-like cells and stellate reticulum [1]. In the 2017 edition, the genetic profile of ameloblastoma was updated broadly. BRAF p.V600E is the most common activating mutation, affecting the MAPK pathways, and is an early and critical event in the etiopathogenesis of ameloblastoma [14,15]. BRAF inhibitor therapy has been proposed for selective cases in the treatment [13,16]. It can be predicted that data on these target therapies will increase and will be included in the next classification.
Adenoid ameloblastoma (AA) is the only new entity added in the odontogenic lesions and it represents the most important change. It is defined as an epithelial odontogenic neoplasm composed of cribriform architecture and ductlike structures, and frequently includes dentinoid (Figure 5C-D). Approximately 40 cases have been reported in the literature so far [17]. It usually presents as a painless swelling with an incidence peak in the 4th decade, and with slight male preference [5,17]. The essential diagnostic criteria have been described as an ameloblastoma-like component, duct-like structures, whorls/morules, and cribriform architecture, while dentinoid, clear cells, focal ghost-cell keratinization are reported as desirable features [1]. Variable staining for CK14, CK19, p40, p16 and p53 has been reported (18). Ki-67 proliferation index is usually high and that can explain the local aggressive behavior with a high recurrence rate (45.5%-70%) [5,17]. Interestingly, in contrast to other intraosseous ameloblastomas, BRAF p.V600E mutations have not been found in AA. The lack of BRAF reactivity and the finding of nuclear β catenin reactivity in these tumors calls into question their relation to ameloblastoma and whether adenoid ameloblastoma is the best designation for this new tumor. The main differential diagnosis for AA includes AOT and DHGT but these tumors do not show the essential criteria of AA. Clear cell odontogenic carcinoma and odontogenic carcinoma with dentinoid are also in the differential diagnosis, but the first tumor includes EWSR1 rearrangement, while distinguishing AA from the latter can be difficult as there are few clear distinctions so far [1].
Metastasizing ameloblastoma, defined as an ameloblastoma that has metastasized despite its benign histopathological appearance [1], is still controversial in terms of its classification. This tumor, which was classified under the odontogenic carcinoma section in 2005 [19], was classified under the benign epithelial odontogenic tumors in 2017 [4], as well as in the current edition. The challenge is characterizing metastasizing ameloblastoma at the molecular level and whether its genotype is sufficiently distinct to allow metastasis despite its bland morphology histologically. The solution of the classification issue, which contradicts its name, seems to be left to the next classification.
Benign Mixed Epithelial & Mesenchymal Odontogenic
Tumors
Odontoma is now considered a hamartomatous odontogenic
lesion with compound and complex types. The
section has a very detailed discussion about ameloblastic
fibroodontoma (AFO) and ameloblastic fibrodentinoma
(AFD), which were excluded from the 2017 and current
classification because most examples were presumed to
represent developing odontomas. However, the presence
of BRAF p.V600E mutations in AFD and AFO similar to
ameloblastic fibroma, but different from odontoma, has
supported the arguments that at least some of these lesions
are in fact neoplastic, particularly those with a locally aggressive
biological behavior, large size, and recurrence [20,21]. A recent study suggests that the combination of age
and lesion size may be used to distinguish between lesions
of a true neoplastic nature (i.e., AFO) and hamartomatous
formation (i.e., OD) [22]. On the other hand, it is obvious
that we need further molecular and genetic specifications
to better understand their true nature.
Primordial odontogenic tumor, a new entity to the 2017 classification does not have any significant changes due to its rarity.
Ameloblastic fibroma also has a detailed discussion about the relationship of AF with AFO, AFD, and odontoma in the histopathology and pathogenesis sections. Both odontoma and ameloblastic fibroma sections of the new edition have a discussion about AFO and AFD compared to previous editions, and this may indicate a need for further clarification of these lesions in the next classification.
Dentinogenic ghost cell tumor is a rare benign odontogenic tumor, which kept its entity status without any important updates.
Benign Mesenchymal Odontogenic Tumors
Odontogenic fibroma now clearly has subtypes; amyloid
subtype, granular cell subtype, ossifying subtype, and
hybrid odontogenic fibroma with central giant cell
granuloma [1]. Amyloid type characterized by amyloid
deposits with Langerhans cells is a well-known entity but
a controversial tumor as pointed out earlier in CEOT and
needs to be classified as a CEOT or odontogenic fibroma,
not both.
Cementoblastoma now has some molecular updates that it shows c-FOS overexpression and harbors the same FOS rearrangement [23] as osteoblastoma, a histologic mimicker. This raises the question of cementoblastoma being a unique odontogenic tumor or a bone neoplasm simply within the spectrum of osteoid osteoma and osteoblastoma.
Cemento-ossifying fibroma (COF) was classified under mesenchymal odontogenic tumors in the 2017 classification for the first time but discussed in detail with the other ossifying fibromas in the fibro-osseous lesions section [4]. While COF has always been a benign fibro-osseous lesion as well as an odontogenic neoplasm, it is now defined and updated under the odontogenic tumor section. A variety of infrequent molecular alterations have been reported in COF but no pathogenic alterations were identified when 50 oncogenes or tumor suppressor genes were examined by NGS [24].
Odontogenic myxoma (OM) has some updates in its pathogenesis that shows MAPK/ERK pathway activation, and this pathway inhibition may have the potential to reduce tumor growth [25]. It is worth emphasizing, as the previous edition did, that the most important differential diagnosis of OM is the dental papilla of a developing tooth or a normal/hyperplastic dental follicle that is almost identical histologically to OM (Figure 6C-D), but familiarity with these anatomic structures and the clinical and radiologic features will avoid misdiagnosis (Figure 6).
Malignant Odontogenic Tumors
There are not many significant differences between the last
two editions of the Blue Book in terms of histopathological
description and classification of malignant odontogenic
tumors. Due to the lack of defined UICC staging guidance,
the use of International Collaboration on Cancer Reporting
minimum data set reporting is encouraged for all malignant
odontogenic tumors [26].
Sclerosing odontogenic carcinoma is a very rare odontogenic carcinoma that was added to the classification in 2017 [4]. Due to the rarity of cases, there are no molecular updates or developments. As a minor change, not having the potential for metastasis was added to the definition of SOC, which was characterized by bland cytology, markedly sclerotic stroma and locally aggressive infiltration [1]. Because the original publication [27] suggested and the WHO now concurs that this neoplasm has no metastatic potential, should it be categorized as a carcinoma?
Ameloblastic carcinoma has a definition change from the previous edition that was accepted and described as a malignant counterpart of ameloblastoma [1]. Now, it is considered a primary odontogenic carcinoma histologically resembling ameloblastoma. BRAF p.V600E mutations, the most common activating mutation in conventional ameloblastoma, have been reported in AC (28) but it has no defined diagnostic value yet.
Clear cell odontogenic carcinoma has no significant changes. It is well known that more than 80% of cases harbor a translocation involving EWSR1 and ATF1 [29], a common pathogenesis also of hyalinizing clear cell carcinoma [30]. The differential diagnosis is broad and includes almost all clear cell rich tumors, including odontogenic tumors, salivary gland tumors, and metastatic tumors, particularly renal cell carcinoma. Distinction may require IHC/ molecular studies in some challenging cases.
Ghost cell odontogenic carcinoma has limited update on molecular aspects because of the rarity of the tumor. In the new edition, a single case-documented mutation of CTNNB1 (β-catenin) [31] has been added to the previous molecular profile including multiple changes in the SHH signaling pathway, and a novel APC mutation [32].
Primary intraosseous carcinoma-NOS is usually squamous carcinoma with variable differentiation, but mostly moderately. A recent systemic review found that the majority arise from odontogenic cysts, more commonly residual and radicular cysts and less often dentigerous and odontogenic keratocysts [33]. This diagnosis should be made carefully after excluding other malignant odontogenic and intraosseous salivary gland tumors, metastatic lesions, and carcinomas invading bone from other anatomic structures.
Odontogenic carcinosarcoma is an extremely rare malignant odontogenic tumor containing both malignant epithelial and mesenchymal components that require very careful examination. Any sarcomatoid change in a malignant epithelial odontogenic tumor should be evaluated carefully to avoid misdiagnosis of a spindle cell odontogenic carcinoma [34].
Odontogenic sarcomas are a group of malignant odontogenic tumors; ameloblastic fibrosarcoma, ameloblastic fibrodentinosarcoma, ameloblastic fibro-odontosarcoma. At least 24% of ameloblastic fibrosarcomas arise in benign AF or recurrent AF (35). Dentin/dentinoid with or without enamel/enameloid matrix is produced in approximately 10% of cases and designated as ameloblastic fibro-dentinosarcoma and ameloblastic fibro-odontosarcoma, respectively [1].
Odontogenic carcinoma with dentinoid [36], is reported but not included as a separate entity in the 2022 classification. It is mentioned frequently in the differential diagnosis of other odontogenic tumors and its justification and placement in the classification remains controversial but an area in need of clarification.
CYSTS OF THE JAWS
Table III highlights the essential diagnostic criteria
along with age, gender, and localization preference of all
odontogenic cysts, surgical ciliated cyst and nasopalatine
duct cyst. In the 2017 classification, the cysts of the jaws
were divided into two primary parts; odontogenic cysts of
inflammatory origin and odontogenic/non-odontogenic
developmental cysts [4]. Now, in the 2022 classification, the
umbrella term of cysts of the jaws has been used without
any subdivision. However, here we prefer to discuss them
under the subheadings of inflammatory odontogenic cysts,
developmental odontogenic cysts, and other cysts of the jaws
for greater clarity and to emphasize their origin.
Table III: Age, gender, localization preferences, and essential diagnostic criteria of jaw cysts, modified from the 2022 WHO classification[1].
Inflammatory Odontogenic Cysts
Radicular cyst (RC) is still the most common cyst of the
jaws and accounts for about 60% of all odontogenic cysts
[37]. RCs arise from periradicular inflammation secondary
to the spread of odontogenic infection resulting from tooth
devitalization. Residual cyst, which was clearly mentioned
as a subtype of RC, is found as a well-defined radiolucency
at a site of previous tooth extraction when the RC was not
removed when the offending tooth was extracted. Lateral
RC terminology of 2017 has been abandoned and only
mentioned as RC that can be located on the lateral aspect
of the root associated with a lateral root canal [1,4].
Inflammatory collateral cysts have no major changes and continue with two distinct subtypes as paradental cyst and mandibular buccal bifurcation cyst. The histology is not specific, and indistinguishable from RC features.
Developmental Odontogenic Cysts
Gingival cysts (adult and infant types), dentigerous cyst
(eruption cyst, a superficial subtype of dentigerous cyst over
an erupting tooth), orthokeratinized odontogenic cyst, lateral
periodontal cyst, and botryoid odontogenic cyst continue in
the 2022 classification without important changes from
the previous edition. Regarding molecular updates, BRAF
p.V600E mutations found in ameloblastomas have not
been found in dentigerous cysts [38].
Calcifying odontogenic cyst (COC) has continued in the cyst classification with an important change in the definition that also affects the diagnostic criteria. In the definition of the 2017 classification, ameloblastoma-like epithelium was excluded and COC is now defined as a developmental odontogenic cyst characterized histologically by ghost cells, which often calcify. While most COCs still have ameloblastoma-like epithelium, that feature was moved from an essential feature to a desired one [39]. Mutations of CTNNB1 which encodes β-catenin has been added to the COC pathogenesis [40].
Glandular odontogenic cyst (GOC) also has some differences from the fourth edition in terms of diagnostic histopathologic features. In 2017, ten different histopathologic features were described and observation of at least seven criteria was suggested to make a GOC diagnosis [4,41]. The new edition emphasized that even if characteristic, not all features are present in all cases but more features provide more confidence in the diagnosis [1]. Among these features, the essential criterion is presence of a lining epithelium with varying thickness, but it was stated that hobnail cells are observed in almost all cases and seem to be the most characteristic feature. It was also emphasized in this classification that the most important differential diagnosis of GOC is intraosseous mucoepidermoid carcinoma. Demonstrating the MAML2 rearrangement for intraosseous MEC is important in the differential diagnosis of these two lesions [42]. That is still generally accepted; however, one GOC case has been reported with MAML2 rearrangement [43]. It is believed that this situation needs further studies.
Odontogenic keratocyst (OKC) is the most frequently researched cyst due to high recurrence rate, aggressive clinical behavior, and association with the nevoid basal cell carcinoma syndrome. In the 2022 edition, OKC continues in the cyst classification and has the longest section among the cysts of the jaw. There is extensive literature characterizing the molecular landscape of OKC. Most show mutations of the tumor suppressor gene PTCH 1, but rarely PTCH2 or SUNU [44-46].
These mutations have fueled the continued spirited debate about whether OKC is a cyst or a cystic neoplasm. In 2005, OKC was changed to a cystic neoplasm and designated a keratocystic odontogenic tumor [19]. It was moved back into the cyst category in 2017 [4] and continues as a cyst in the 5th current classification. The debate continues.
Other Cysts of the Jaws
Surgical ciliated cyst, not a new entity but new to the
classification, is a rare non-odontogenic cyst lined
by respiratory epithelium as a result of the traumatic
implantation of sinus or nasal mucosa. Surgical ciliated cyst
of the maxilla, postoperative maxillary cyst or (respiratory)
implantation cyst are other terms used for this entity.
The most common age range is the 5th to 6th decades with
no gender predilection [47]. As the definition indicates,
it occurs most commonly in the posterior maxilla; but
very rarely in the mandible due to implantation of sinus
epithelium by contaminated instruments or using nasal
bone or cartilage with epithelium for augmentation
genioplasty [47,48]. Histopathologically, the cyst is lined by
ciliated pseudostratified columnar epithelium and mucous cells are common (Figure 13B-D). A history of previous
surgery is an essential criterion for diagnosis. Treatment is
simple enucleation and recurrence is rare.
Nasopalatine duct cyst is the most common nonodontogenic cyst of the jaws (about 80%) [37,49]. The cyst is lined by non-keratinized squamous epithelium or respiratory epithelium in variable proportion with focal areas of cuboidal, columnar, or ciliated changes. Generally, the neurovascular bundle is seen in the wall of the cyst, but this is a feature of sectioning and this feature is included in the desirable diagnostic criteria [1].
In conclusion, the new 2022 WHO classification of odontogenic tumors and jaw cysts includes some modifications and developments that we briefly summarized. It is hoped that this summary becomes a resource for readers to find recent changes and critical diagnostic information. Lastly, rapid developments in technology and molecular fields signal that the time between the editions of WHO classification of Head and Neck Tumours (1st 1971, 2nd 1992, 3rd 2005, 4th 2017 and 5th 2022) will become shorter, and new classifications seem inevitable in the next 5 years.
Conflict of Interest
The authors have declared no conflict of interest.
1) WHO Classification of Tumours Editorial Board. Head and neck
tumours [Internet; beta version ahead of print]. Lyon (France):
International Agency for Research on Cancer; 2022. (WHO
classification of tumours series, 5th ed.; vol. 9). Available from:
https://tumourclassification.iarc.who.int/chapters/52.
2) Vered M, Wright JM. Update from the 5th Edition of the World
Health Organization classification of head and neck tumors:
odontogenic and maxillofacial bone tumours. Head Neck Pathol.
2022;16:63-75.
3) Soluk-Tekkeşin M, Wright JM. The World Health Organization
classification of odontogenic lesions: A summary of the changes
of the 2017 (4th) edition. Turk Patoloji Derg. 2018;34(1).
4) Odontogenic and maxilofacial bone tumours. In: El-naggar
ak, Chan JkC, Grandis Jr, Takata T, Slootweg P, editors. WHO
classification of head and neck tumours. 4th ed. lyon: IARC;
2017. 205-60.
5) Loyola AM, Cardoso SV, de Faria PR, Servato JP, Eisenberg
AL, Dias FL, Thavaraj S, Gomes CC, Gomez RS. Adenoid
ameloblastoma: Clinicopathologic description of five cases and
systematic review of the current knowledge. Oral Surg Oral Med
Oral Pathol Oral Radiol. 2015;120:368-77.
6) Vargas PA, Carlos-Bregni R, Mosqueda-Taylor A, Cuairan-
Ruidíaz V, Lopes MA, de Almeida OP. Adenomatoid dentinoma
or adenomatoid odontogenic hamartoma: What is the better
term to denominate this uncommon odontogenic lesion? Oral
Dis. 2006;12:200-3.
7) Mosqueda-Taylor A, Carlos-Bregni R, Ledesma-Montes C,
Fillipi RZ, de Almeida OP, Vargas PA. Calcifying epithelial
odontogenic tumor-like areas are common findings in
adenomatoid odontogenic tumors and not a specific entity. Oral
Oncol. 2005;41:214-5.
8) Coura BP, Bernardes VF, de Sousa SF, França JA, Pereira NB,
Pontes HAR, Batista AC, da Cruz Perez DE, Albuquerque Junior
RLC, de Souza LB, Martins MD, Diniz MG, Gomez RS, Gomes
CC. KRAS mutations drive adenomatoid odontogenic tumor
and are independent of clinicopathological features. Mod Pathol.
2019;32:799-806.
9) Zhou CX, Li TJ. A clinicopathologic study on central odontogenic
fibroma: With special reference to amyloid variant. Oral Surg
Oral Med Oral Pathol Oral Radiol. 2018;126:513-20.
10) Philipsen HP, Reichart PA. Unicystic ameloblastoma. A review
of 193 cases from the literature. Oral Oncol. 1998;34:317-25.
11) Heikinheimo K, Huhtala JM, Thiel A, Kurppa KJ, Heikinheimo
H, Kovac M, Kragelund C, Warfvinge G, Dawson H, Elenius K,
Ristimäki A, Baumhoer D, Morgan PR. The mutational profile of
unicystic ameloblastoma. J Dent Res. 2019;98:54-60.
12) Zlotogorski-Hurvitz A, Soluk Tekkeşin M, Passador-Santos F,
Martins Montalli VA, Salo T, Mauramo M, Kats L, Buchner A,
Vered M. Conceptual changes in ameloblastoma: Suggested reclassification
of a veteran tumor. Oral Dis. 2022;28:703-10.
13) Hirschhorn A, Campino GA, Vered M, Greenberg G, Yacobi
R, Yahalom R, Barshack I, Toren A, Amariglio N, Rechavi G.
Upfront rational therapy in BRAF V600E mutated pediatric
ameloblastoma promotes ad integrum mandibular regeneration.
J Tissue Eng Regen Med. 2021;15:1155-61.
14) Brown NA, Betz BL. Ameloblastoma: A review of recent molecular
pathogenetic discoveries. Biomark Cancer. 2015;7(Suppl 2):19-24.
15) Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski
J, Elenius K, Heikinheimo K. High frequency of BRAF V600E
mutations in ameloblastoma. J Pathol. 2014;232:492-8.
16) Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW.
Clinical and radiographic response with combined BRAFtargeted
therapy in stage 4 ameloblastoma. J Natl Cancer Inst.
2014;107:378.
17) Jayasooriya PR, Abeyasinghe WAMUL, Liyanage RLPR,
Uthpali GN, Tilakaratne WM. Diagnostic enigma of adenoid
ameloblastoma: Literature review based evidence to consider it
as a new sub type of ameloblastoma. Head Neck Pathol. 2021 Jul 19.
18) Adorno-Farias D, Muniz VRVM, Soares AP, Cury PR, Rabelo
RG, Fernández-Ramires R, de Azevedo RA, Dos Santos JN.
Ameloblastoma with adenoid features: A series of eight cases.
Acta Histochem. 2018;120:468-76.
19) Odontogenic tumors. In: Barnes L, Eveson J, Reichart P,
Sidransky D, editors. World Health Organization classification.
Pathology and genetics of head and neck tumors. 3rd ed. lyon:
IarC Press; 2005. 283-327.
20) Coura BP, Bernardes VF, de Sousa SF, Diniz MG, Moreira RG,
de Andrade BAB, Romañach MJ, Pontes HAR, Gomez RS, Odell
EW, Gomes CC. Targeted next-generation sequencing and allelespecific
quantitative PCR of laser capture microdissected samples
uncover molecular differences in mixed odontogenic tumors. J
Mol Diagn. 2020;22:1393-9.
21) Kirjavainen A, Tuovinen V, Sándor GK. Large ameloblastic
fibro-odontoma in a 7-year-old girl with analysis of 108 cases.
Ann Maxillofac Surg. 2016;6:15-20.
22) Soluk-Tekkesin M, Vered M. Ameloblastic fibro-odontoma:
At the crossroad between developing odontoma and true
odontogenic tumour. Head Neck Pathol. 2021;15:1202-11.
23) Lam SW, Cleven AHG, Briaire-de Bruijn IH, Schreuder WH,
Kroon HM, Savci-Heijink DC, Suurmeijer AJH, Szuhai K, Bovée
JVMG, Baumhoer D. FOS rearrangement and expression in
cementoblastoma. Am J Surg Pathol. 2021;45:690-3.
24) Pereira TDSF, Diniz MG, França JA, Moreira RG, Menezes
GHF, Sousa SF, Castro WH, Gomes CC, Gomez RS. The Wnt/β-
catenin pathway is deregulated in cemento-ossifying fibromas.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:172-8.
25) Pereira NB, Bastos VC, de Souza JC, Diniz MG, Vitório JG,
Kitten GT, de Oliveira Andrade L, de Avelar GF, Castro WH,
Bernardes VF, Dias AAM, Gomez RS, Gomes CC. First insights
for targeted therapies in odontogenic myxoma. Clin Oral
Investig. 2020;24:2451-8.
26) Slootweg PJ, Odell EW, Baumhoer D, Carlos R, Hunter KD,
Taylor AM, Richardson MS, Slater L, Speight PM, Wright
J, Thompson LDR. Data set for the reporting of malignant
odontogenic tumors: Explanations and recommendations of
the guidelines from the International Collaboration on Cancer
Reporting. Arch Pathol Lab Med. 2019;143:587-92.
27) Koutlas IG, Allen CM, Warnock GR, Manivel JC. Sclerosing
odontogenic carcinoma: A previously unreported variant of
a locally aggressive odontogenic neoplasm without apparent
metastatic potential. Am J Surg Pathol. 2008;32:1613-9.
28) Niu Z, Li Y, Chen W, Zhao J, Zheng H, Deng Q, Zha Z, Zhu H,
Sun Q, Su L. Study on clinical and biological characteristics of
ameloblastic carcinoma. Orphanet J Rare Dis. 2020;15:316.
29) Bilodeau EA, Weinreb I, Antonescu CR, Zhang L, Dacic S, Muller
S, Barker B, Seethala RR. Clear cell odontogenic carcinomas show
EWSR1 rearrangements: A novel finding and a biological link to
salivary clear cell carcinomas. Am J Surg Pathol. 2013;37:1001-5.
30) Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, Jordan
RC, Perez-Ordoñez B, Have C, Asa SL, Leong IT, Bradley G, Klieb
H, Weinreb I. EWSR1-ATF1 fusion is a novel and consistent
finding in hyalinizing clear-cell carcinoma of salivary gland.
Genes Chromosomes Cancer. 2011;50:559-70.
31) Rappaport MJ, Showell DL, Edenfield WJ. Metastatic ghost cell
odontogenic carcinoma: Description of a case and search for
actionable targets. Rare Tumors. 2015;7:5813.
32) Bose P, Pleasance ED, Jones M, Shen Y, Chng C, Reisle C,
Schein JE, Mungall AJ, Moore R, Ma Y, Sheffield BS, Thomson
T, Rasmussen S, Ng T, Yip S, Lee CW, Ho C, Laskin J, Marra MA,
Jones SJ. Integrative genomic analysis of ghost cell odontogenic
carcinoma. Oral Oncol. 2015;51:e71-5.
33) de Morais EF, Carlan LM, de Farias Morais HG, Pinheiro JC,
Martins HDD, Barboza CAG, de Almeida Freitas R. Primary
intraosseous squamous cell carcinoma involving the jaw bones:
A systematic review and update. Head Neck Pathol. 2021;15:608-16.
34) McLean-Holden AC, Bishop JA, Kessler HP, Myers LL, Radwan
AM, Wildey TC, Wright JM, Cheng YL. Spindle-cell variant of
ameloblastic carcinoma: A report of 3 cases and demonstration
of epithelial-mesenchymal transition in tumor progression. Oral
Surg Oral Med Oral Pathol Oral Radiol. 2019;128:e113-e121.
35) Chrcanovic BR, Brennan PA, Rahimi S, Gomez RS. Ameloblastic
fibroma and ameloblastic fibrosarcoma: A systematic review. J
Oral Pathol Med. 2018;47:315-25.
36) Mosqueda-Taylor A, Neville BW, Tatemoto Y, Ogawa I, Takata
T. Odontogenic carcinoma with dentinoid: A new odontogenic
carcinoma. Head Neck Pathol. 2014;8:421-31.
37) Tekkesin MS, Olgac V, Aksakalli N, Alatli C. Odontogenic and
nonodontogenic cysts in Istanbul: Analysis of 5088 cases. Head
Neck. 2012;34:852-5.
38) Pereira NB, Pereira KM, Coura BP, Diniz MG, de Castro WH,
Gomes CC, Gomez RS. BRAFV600E mutation in the diagnosis
of unicystic ameloblastoma. J Oral Pathol Med. 2016;45:780-5.
39) Nel C, Robinson L, Roza ALOC, Vargas PA, Nortjé CJ,
van Heerden WF. Calcifying odontogenic cysts: A 20-year
retrospective clinical and radiological review. Dentomaxillofac
Radiol. 2021;50:20200586.
40) Yukimori A, Oikawa Y, Morita KI, Nguyen CT, Harada H,
Yamaguchi S, Kayamori K, Yamaguchi A, Ikeda T, Sakamoto K.
Genetic basis of calcifying cystic odontogenic tumors. PLoS One.
2017;12:e0180224.
41) Fowler CB, Brannon RB, Kessler HP, Castle JT, Kahn MA.
Glandular odontogenic cyst: Analysis of 46 cases with special
emphasis on microscopic criteria for diagnosis. Head Neck
Pathol. 2011;5:364-75.
42) Bishop JA, Yonescu R, Batista D, Warnock GR, Westra
WH. Glandular odontogenic cysts (GOCs) lack MAML2
rearrangements: A finding to discredit the putative nature of
GOC as a precursor to central mucoepidermoid carcinoma.
Head Neck Pathol. 2014;8:287-90.
43) Greer RO, Eskendri J, Freedman P, Ahmadian M, Murakami-
Walter A, Varella-Garcia M. Assessment of biologically aggressive,
recurrent glandular odontogenic cysts for mastermind-like 2
(MAML2) rearrangements: Histopathologic and fluorescent in
situ hybridization (FISH) findings in 11 cases. J Oral Pathol Med.
2018;47:192-7.
44) Li TJ. The odontogenic keratocyst: A cyst, or a cystic neoplasm? J
Dent Res. 2011;90:133-42.
45) Qu J, Yu F, Hong Y, Guo Y, Sun L, Li X, Zhang J, Zhang H, Shi R,
Chen F, Li T. Underestimated PTCH1 mutation rate in sporadic
keratocystic odontogenic tumors. Oral Oncol. 2015;51:40-5.
46) Qu J, Zhang J, Zhang H, Li X, Hong Y, Zhai J, Wang Y, Chen
F, Li T. PTCH1 alterations are frequent but other genetic
alterations are rare in sporadic odontogenic keratocysts. Oral
Dis. 2019;25:1600-7.
47) Kahn A, Matalon S, Bassam Salem R, Kats L, Chaushu L, Vered
M, Rosen E. Sinus floor augmentationassociated surgical
ciliated cysts: Case series and a systematic review of the literature.
Appl Sci. 2021;11:1903.